* product image indicative of product only, actual product may differ in appearance.
10 minute pre-analysis process
Removes the uncertainty of DOACs from your decisions
Current research investigates use in whole blood
DOAC-Stop™ is now offered for simplifying diagnostic problems associated with DOACs. DOACs are known to interfere with almost all clotting tests to varying degrees and sometimes patients who need to be tested for underlying coagulation defects may also be on DOACs. Specific antidotes for individual DOACs are being developed for therapeutic use but are not yet widely available for laboratory use. DOAC-Stop™ is first of its kind to extract all types of new Direct Oral Anti-Coagulant (DOACs) including dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban and also argatroban from test plasmas with minimal effect on plasma proteins involved in the clotting mechanism. It absorbs up to an estimated 2,000ng/ml of any DOAC in less than 10 minutes. Unlike therapeutic additives for reversing DOACs it leaves no residual effect. It can be used for checking if DOACs are present in samples giving unexpectedly prolonged clotting test or abnormal chromogenic test results. There is negligible interference with vitamin K antagonist or heparinoid anticoagulants. Plasmas treated with DOAC-Stop™ can be used for valid factor assays and in testing for thrombotic risk. In particular it can prevent false LAC positive results due to DOACs or other agents in testing for lupus anticoagulants. We guarantee a competitive price for our reagents.
See haematex.com/eifu for CE Marked instructions in multiple languages.
1. Novelli C, et al. Direct oral anticoagulant adsorption and laboratory detection of lupus anticoagulant. Blood Coagul. Fibrinolysis. 2023; 34(3): 199-205.
2. Wang, J, Lim, HY, Nandurkar, H, Ho, P. DOAC-stop can remove direct oral anticoagulants and allow analysis by global coagulation assays. Int J Lab Hematol. 2023; 1- 8.
3. Savola P, Lemponen M, Joutsi-Korhonen L, Helin TA. Novel Ex Vivo DOAC Removal Methods Reduce Interference in Lupus Anticoagulant Testing. Diagnostics. 2022; 12(10):2520.
4. Taune, V., Skeppholm, M., Ågren, A., Wikman, A., Hillarp, A., & Wallén, H. Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop. TH Open. 2022;6(3):e238-e247.
5. Ong J, et al. A review of laboratory considerations in thrombophilia testing Pathology, 2022.
6. Scalambrino E, et al. Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection in plasma containing argatroban Int J Lab Hematol, 44: e204-e207.
7. Szabó G, et al. Laboratory Approaches to Test the Function of Antiphospholipid Antibodies Semin Thromb Hemost 2022; 48(02): 132-144
8. Khider L, et al. Inherited Thrombophilia in the Era of Direct Oral Anticoagulants Int. J. Mol. Sci. 2022, 23(3), 1821;
9. Tripodi A, et al. Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection Thrombosis Research. August 2021. Vol 204. P32-39.
10. Douxfils J, et al. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants Thromb Haemost 2021; 121(08): 1008-1020.
11. Baker S, et al. DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples Res Pract Thromb Haemost. 2021; 5: 314– 325.
12. Siriez R, et al. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory Int J Lab Hematol. 2021; 43: 7– 20.
13. Exner T, et al. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. International Journal Laboratory Hematology 2020;00:1–8.
14. Favaloro E, et al. Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. Thrombosis Research 180 (2019) 10–19
15. Slavic L, et al. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban. Clinical and Applied Thrombosis/Hemostasis. 2019; Volume 25: 1-6
16. Zabczyk M, et al. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants. De Gruyter Clin Chem Lab Med 2019;
17. Exner T, et al. Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging agents. Clin Chem Lab Med. 2019; 57: 690-696.
18. Exner T, et al. Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent. Thromb Res 2019; 179: 69-72
19. Favresse J, et al. Evaluation of the DOAC Stop procedure to overcome the effect of DOACs on several thrombophilia screening tests. TH Open, 2018; 2: e202-e209.
20. Jacquemin M, et al. The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays. Int. J. Lab. Haematol. 2018; 40: 442-447.
21. Kopatz WF, et al. Use of DOAC Stop for elimination of anticoagulants in thrombin generation assays. Thromb. Res. 2018; 170: 97-101.
22. Platton S, Hunt C. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban. Int J Lab Haematol. 2018; 1-7.
23. Exner T, et al. Simple method for removing DOACs from plasma samples Thromb. Res. 2018; 163: 117-122.
Use this form to send us a message.
*All fields are required.
